Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | AGIO |
---|---|---|
09:32 ET | 4349 | 43.495 |
09:34 ET | 200 | 43.25 |
09:36 ET | 100 | 43.325 |
09:38 ET | 115 | 43.275 |
09:39 ET | 200 | 43.38 |
09:41 ET | 200 | 43.305 |
09:43 ET | 100 | 43.62 |
09:45 ET | 169 | 43.79 |
09:48 ET | 200 | 43.85 |
09:50 ET | 300 | 43.65 |
09:52 ET | 200 | 43.7285 |
09:54 ET | 600 | 43.74 |
09:56 ET | 100 | 44.02 |
09:57 ET | 1160 | 43.96 |
09:59 ET | 500 | 44.015 |
10:01 ET | 100 | 44.11 |
10:03 ET | 900 | 44.09 |
10:06 ET | 100 | 44.075 |
10:08 ET | 200 | 44.105 |
10:10 ET | 2400 | 44.17 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Agios Pharmaceuticals Inc | 2.5B | -7.0x | --- |
MoonLake Immunotherapeutics | 2.6B | -55.4x | --- |
IDEAYA Biosciences Inc | 2.7B | -17.3x | --- |
Celldex Therapeutics Inc | 2.4B | -13.0x | --- |
SpringWorks Therapeutics Inc | 2.7B | -7.0x | --- |
Geron Corp | 2.7B | -12.8x | --- |
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of alpha- and beta- thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.5B |
---|---|
Revenue (TTM) | $29.4M |
Shares Outstanding | 56.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.79 |
EPS | $-6.31 |
Book Value | $14.50 |
P/E Ratio | -7.0x |
Price/Sales (TTM) | 86.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,336.42% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.